| PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson, BB Li, S Xie, ... Cell reports 25 (11), 2972-2980. e5, 2018 | 493 | 2018 |
| LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer D Wang, L Ding, L Wang, Y Zhao, Z Sun, RJ Karnes, J Zhang, H Huang Oncotarget 6 (38), 41045, 2015 | 198 | 2015 |
| BRCA1 is a negative modulator of the PRC2 complex L Wang, X Zeng, S Chen, L Ding, J Zhong, JC Zhao, L Wang, A Sarver, ... The EMBO journal 32 (11), 1584-1597, 2013 | 136 | 2013 |
| STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer Q Wang, JS Bergholz, L Ding, Z Lin, SK Kabraji, ME Hughes, X He, S Xie, ... Nature Communications 13 (1), 3022, 2022 | 134 | 2022 |
| p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis J Zhong, L Ding, LR Bohrer, Y Pan, P Liu, J Zhang, TJ Sebo, RJ Karnes, ... Cancer research 74 (6), 1870-1880, 2014 | 118 | 2014 |
| Carbonyl reductase 1 as a novel target of (−)‐epigallocatechin gallate against hepatocellular carcinoma W Huang, L Ding, Q Huang, H Hu, S Liu, X Yang, X Hu, Y Dang, S Shen, ... Hepatology 52 (2), 703-714, 2010 | 81 | 2010 |
| Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability W Jiang, H Huang, L Ding, P Zhu, H Saiyin, G Ji, J Zuo, D Han, Y Pan, ... Oncogene 34 (34), 4460-4470, 2015 | 76 | 2015 |
| EZH 2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis Y Zhao, L Ding, D Wang, Z Ye, Y He, L Ma, R Zhu, Y Pan, Q Wu, K Pang, ... The EMBO journal 38 (5), e99599, 2019 | 75 | 2019 |
| Inhibition of EZH2 by chemo-and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer C Wu, X Jin, J Yang, Y Yang, Y He, L Ding, Y Pan, S Chen, J Jiang, ... Oncotarget 7 (3), 3440, 2015 | 56 | 2015 |
| CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy L Ding, S Chen, P Liu, Y Pan, J Zhong, KM Regan, L Wang, C Yu, ... Cancer research 74 (7), 2050-2061, 2014 | 55 | 2014 |
| STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer L Ding, Q Wang, A Martincuks, MJ Kearns, T Jiang, Z Lin, X Cheng, ... Journal for immunotherapy of cancer 11 (1), 2023 | 52 | 2023 |
| Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma S Liu, L Ma, W Huang, Y Shai, X Ji, L Ding, Y Liu, L Yu, S Zhao Cellular & molecular biology letters 11, 230-241, 2006 | 24 | 2006 |
| Suppression of casein kinase 2 sensitizes tumor cells to antitumor TRAIL therapy by regulating the phosphorylation and localization of p65 in prostate cancer X Gang, Y Wang, Y Wang, Y Zhao, L Ding, J Zhao, L Sun, G Wang Oncology Reports 34 (3), 1599-1604, 2015 | 8 | 2015 |
| PARP inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer. Cell Rep. 2018; 25: 2972–2980. e5 L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson | 5 | 2021 |
| PARP Inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell Rep. 2018; 25 (11): 2972-80 e5 L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson, BB Li, S Xie, ... | 5 | |
| PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018; 25: 2972–80. e5 L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson, BB Li, S Xie, ... | 4 | |
| (−)-Epigallocatechin-3-gallate, a potential inhibitor to human dicarbonyl/l-xylulose reductase XH Hu, LY Ding, WX Huang, XM Yang, F Xie, M Xu, L Yu The journal of biochemistry 154 (2), 167-175, 2013 | 3 | 2013 |
| LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 2015; 6: 41045–41055 D Wang, L Ding, L Wang, Y Zhao, Z Sun, RJ Karnes, J Zhang, H Huang External Resources Pubmed/Medline (NLM) Crossref (DOI), 0 | 3 | |
| PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor. L Ding, Q Wang, M Kearns, T Jiang, P Konstantinopoulos, U Matulonis, ... CLINICAL CANCER RESEARCH 26 (13), 23-23, 2020 | 1 | 2020 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TARGET CANCER INCLUDING BRCA-SPECIFIC siRNA AS ACTIVE INGREDIENT JH Ryu, IC Kwon, Y KO, TM Roberts, JJ Zhao, L Ding US Patent App. 18/745,018, 2025 | | 2025 |
